Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II chemoradiation for unresectable T4 esophageal cancer
NL-OMON20123Phase 2Active, not recruiting
- Sponsor
- Not applicable
- Start
- Oct 2003
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in esophageal cancer and esophagogastric junction cancer, sponsored by Not applicable. Primary endpoints: Clinically complete biopsy-proven response rate and Toxicity. Started Oct 2003; status: active, not recruiting.
02
Drugs
paclitaxelcarboplatin
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON20123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20123.